Kaskela Law LLC is investigating potential breach of fiduciary duty claims concerning Humana Inc. (NYSE: HUM) (“Humana”) on behalf of the company’s long-term shareholders.

Recently a federal securities fraud complaint was filed against Humana on behalf of certain investors who purchased shares of the company’s stock between July 27, 2022 and October 1, 2024 (the “Class Period”).  According to the complaint, during the Class Period, Humana and certain senior executive officers issued a series of materially false and misleading statements to investors about the company’s core Medicare Advantage business.

As further detailed in the complaint, the truth regarding Humana’s increased utilization began to emerge in June 2023, causing a series of stock price declines in the latter half of 2023 and during fiscal 2024.

In light of the foregoing, Kaskela Law’s investigation seeks to determine whether Humana’s officers and directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.

Current Humana shareholders who have continuously held HUM shares since at least July 27, 2022 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, by email at [email protected], or by completing the form on this page.